Arena Pharmaceuticals, Inc. (ARNA): Are Investors Worried?

Page 2 of 2

Eisai’s new direct-to-consumer advertisements may help drive prescriptions — some doctors will prescribe drugs if asked even if they wouldn’t have initiated it if the patient didn’t ask — but there’s still the sticker shock of paying for the drugs for the majority of people who aren’t covered by insurance.

It’s going to take time to convince doctors and insurers that the drugs are worth prescribing and paying for. Orexigen Therapeutics, Inc. (NASDAQ:OREX) and Takeda, which hopefully will be able to launch their obesity drug, Contrave, next year, might end up having the best initial launch of the three, walking into a market primed by Eisai and VIVUS, Inc. (NASDAQ:VVUS) and learning from what’s worked for them.

The article An Article About a Press Release About an Advertisement originally appeared on Fool.com.

Fool contributor Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. 

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Page 2 of 2